drugset
drugset / Trial / NCT04890509

A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients

NCT04890509 ↗

Phase 2 Completed 115 enrolled BerGenBio ASA
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of the study is to evaluate the efficacy of bemcentinib as an add-on therapies to standard of care (SoC) in participants hospitalized with coronavirus disease 2019 (COVID-19).

Timeline

Start
2020-10-20
Primary completion
2021-05-25
Completion
2021-05-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemcentinib Small molecule — Oral

Indications

COVID-19